Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants
Open Access
- 27 January 2012
- journal article
- research article
- Published by Springer Nature in BMC Pediatrics
- Vol. 12 (1), 10
- https://doi.org/10.1186/1471-2431-12-10
Abstract
Background The optimal treatment regimen or protocol for managing a persistent patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants has not been well established. This study was aimed at evaluating the failure rate of a cyclooxygenase (COX) inhibitor (COI) for PDA closure and to determine the incidence of a PDA requiring ligation in ELBW infants. We examined the clinical characteristics and risk factors that may predict the clinical consequences of failure of PDA closure by COI. Methods Medical information on 138 infants with birth weight (BW) < 1000 gm who survived for > 48 hours was retrieved. Clinical characteristics and outcomes of patients whose PDAs closed with COI were compared with those who did not close. Results Of the 138 patients, 112 survived to discharge. Eighty (71.4%) of those who survived received 1-3 courses of COI treatment for a symptomatic PDA. A total of 32 (40%) failed COI treatment and underwent PDA ligation. Multivariable logistic regression analysis suggests that the observed differences in the outcomes in infants with or without symptomatic PDA can be explained by the babies with symptomatic PDA being more immature and sicker. No significant difference was seen in the incidence of chronic lung disease (CLD) in infants whose PDA was treated medically versus those who failed medical treatment and then underwent ligation. However, after adjusting for disease severity and other known risk factors, the odds ratio of developing CLD for surviving babies with a persistent PDA compared to those whose PDA was successfully closed with 1-2 courses of COI is 3.24 (1.07-9.81; p = 0.038). Conclusions When successfully treated, PDA in ELBW infants did not contribute significantly to the adverse outcomes such as CLD, retinopathy of prematurity (ROP) and age at discharge. This suggests that it is beneficial for a hemodynamically significant PDA to be closed. The failure of a repeat course of COI to close a PDA is a major risk factor for developing CLD in ELBW infants.Keywords
This publication has 28 references indexed in Scilit:
- Patent ductus arteriosus in the preterm infant: to treat or not to treat?Journal of Perinatology, 2010
- B-Type Natriuretic Peptide Predicts Responses to Indomethacin in Premature Neonates with Patent Ductus ArteriosusThe Journal of Pediatrics, 2010
- Early Surgical Ligation Versus a Conservative Approach for Management of Patent Ductus Arteriosus That Fails to Close after Indomethacin TreatmentThe Journal of Pediatrics, 2010
- Patent Ductus Arteriosus of the Preterm InfantPediatrics, 2010
- Duration of Indomethacin Treatment of the Preterm Patent Ductus Arteriosus as Directed by EchocardiographyThe Journal of Pediatrics, 2009
- The Role of Patent Ductus Arteriosus Ligation in Bronchopulmonary Dysplasia: Reexamining a Randomized Controlled TrialThe Journal of Pediatrics, 2009
- Understanding Intestinal Vulnerability to Perforation in the Extremely Low Birth Weight InfantPediatric Research, 2009
- CRIB II: an update of the clinical risk index for babies scoreThe Lancet, 2003
- A comparison of indices of respiratory failure in ventilated preterm infantsArchives of Disease in Childhood: Fetal & Neonatal, 2000
- Risk Factors for Chronic Lung Disease in the Surfactant Era: A North Carolina Population-based Study of Very Low Birth Weight InfantsPediatrics, 1999